Anti-HAPLN1 / Hyaluronan and proteoglycan link protein 1

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. HAPLN1 antibody detects Hyaluronan and proteoglycan link protein 1, an extracellular matrix (ECM) glycoprotein essential for stabilizing aggregates of hyaluronan and chondroitin sulfate proteoglycans. HAPLN1 promotes structural integrity of cartilage, brain ECM, and connective tissue by maintaining the association between hyaluronan and aggrecan. The HAPLN1 antibody is widely used in developmental biology, neurobiology, and cartilage research to examine ECM organization and tissue morphogenesis.HAPLN1 is encoded by the HAPLN1 gene on human chromosome 5q14.3. The protein is approximately 38 kilodaltons and belongs to the link protein family characterized by tandem immunoglobulin-like domains. HAPLN1 forms ternary complexes with hyaluronan and aggrecan, contributing to the viscoelastic properties of cartilage and the structural framework of the brain extracellular matrix. It is critical for the assembly of perineuronal nets, specialized ECM structures that regulate neuronal excitability and plasticity.Using the HAPLN1 antibody, researchers can detect the protein by western blot, where it appears as a 38?40 kilodalton band, or by immunohistochemistry, where it localizes to extracellular matrix regions of cartilage, brain, and developing tissues. HAPLN1 expression begins early in embryogenesis, marking sites of cartilage condensation and neural patterning. In adults, it contributes to the stability of mature ECM networks, particularly within articular cartilage and neuronal environments. Loss or alteration of HAPLN1 disrupts ECM cohesion, leading to joint instability or impaired neuronal function.HAPLN1 has clinical relevance in osteoarthritis, rheumatoid arthritis, and neurodegenerative diseases. Decreased HAPLN1 levels correlate with cartilage degradation and ECM disorganization. In the nervous system, reduced expression is linked to increased synaptic plasticity and neuroinflammation. Conversely, HAPLN1 overexpression may promote fibrotic ECM accumulation. NSJ Bioreagents provides a validated HAPLN1 antibody, supporting research into tissue architecture, ECM remodeling, and matrix-protein interactions in both health and disease.